Description
In this exclusive session, Thomas Berg and his panelists examine the intricate world of intrahepatic Cholangiocarcinoma (iCCA), following the publication of the EASL clinical practice guidelines on iCCA in 2023. This discussion aim at raising awareness and promoting a deeper understanding of this complex condition, while touching upon the topic of targeted therapies, highlighting the advancements and challenges that lie ahead.
Faculty
- Thomas Berg (Moderator)
- Katie Kelley (Faculty)
- Daniela Sia (Faculty)
- Juan Valle (Faculty)
This episode is scheduled in honour of the World CCA Day (15 February) and the US CCA Awareness Month.
Related episodes
- EASL Studio S5E13: Basics in decision-making for liver cancer treatment
- EASL Studio from EASL Congress 2023: Highlights of the liver cancer research at EASL Congress 2023
- EASL Studio S4E16: Highlights from the EASL Liver Cancer Summit 2023
- EASL Studio S4 Special Edition 1: A new strategy for liver cancer screening: EASL Policy Statement on risk-based surveillance
- EASL Studio S3E16: Liver cancer in 2022: Wrap-up & outlook
- EASL Studio S3E8: Transplanting patients with cancer – Is there a limit?
ℹ️ Please click here to access the podcast version of this EASL Studio episode.